tiprankstipranks
Trending News
More News >
PainReform (PRFX)
NASDAQ:PRFX
US Market
Advertisement

PainReform (PRFX) Price & Analysis

Compare
237 Followers

PRFX Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Product EfficacyPRF-110 was found to statistically significantly reduce pain over the first 48-hours.
Bears Say
Financial NeedsPainReform may need additional capital to complete necessary studies, but there are concerns about the ability to raise capital given current market conditions.
Market CompetitionThe recent approval of a generic version of Exparel, the market leader, impacts the market opportunity for PainReform's PRF-110.

PainReform News

PRFX FAQ

What was PainReform’s price range in the past 12 months?
PainReform lowest stock price was $1.25 and its highest was $16.63 in the past 12 months.
    What is PainReform’s market cap?
    PainReform’s market cap is $2.92M.
      When is PainReform’s upcoming earnings report date?
      PainReform’s upcoming earnings report date is Feb 27, 2026 which is in 176 days.
        How were PainReform’s earnings last quarter?
        Currently, no data Available
        Is PainReform overvalued?
        According to Wall Street analysts PainReform’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does PainReform pay dividends?
          PainReform does not currently pay dividends.
          What is PainReform’s EPS estimate?
          PainReform’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does PainReform have?
          PainReform has 2,013,141 shares outstanding.
            What happened to PainReform’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of PainReform?
            Currently, no hedge funds are holding shares in PRFX

            Company Description

            PainReform

            PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

            PainReform (PRFX) Earnings & Revenues

            Similar Stocks
            Company
            Price & Change
            Follow
            China Pharma Holdings
            Sonoma Pharmaceuticals
            Evoke Pharma
            RedHill Biopharma
            Sunshine Biopharma

            Ownership Overview

            0.22%0.64%99.36%
            Insiders
            0.64% Other Institutional Investors
            99.36% Public Companies and
            Individual Investors

            Options Prices

            Currently, No data available
            ---
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis